Although both clinical experience and formal studies confirm the efficacy of cognitive-behavioral therapy (CBT) and hypnotic medications as treatments for insomnia, the interaction of the 2 treatments when combined has not been fully clarified. In principle, they could potentiate each other, not interact at all (in which case the benefits would be the sum of the 2 treatments alone), or inhibit each other. In this review, I suggest that the weight of available evidence indicates that the 2 treatments have a beneficial interaction, but that the paucity of data should prevent excessive generalization. It would be desirable for future studies to employ newer hypnotics with a range of doses in both nightly and p.r.n. administration and to examine comorbid as well as primary insomnias. The manner in which the medication is presented to the patient and the caregiver's conviction regarding the effectiveness of therapy need to be carefully controlled. Studies that consider these issues will need to be performed before firmer conclusions can be reached.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Barcoded Hybrids of Extracellular Vesicles and Lipid Nanoparticles for Multiplexed Analysis of Tissue Distribution.
Adv Sci (Weinh)
January 2025
Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal, 43150, Sweden.
Targeted delivery of therapeutic agents is a persistent challenge in modern medicine. Recent efforts in this area have highlighted the utility of extracellular vesicles (EVs) as drug carriers, given that they naturally occur in bloodstream and tissues, and can be loaded with a wide range of therapeutic molecules. However, biodistribution and tissue tropism of EVs remain difficult to study systematically.
View Article and Find Full Text PDFDNA damage response mutations enhance the antitumor efficacy of ATR and PARP inhibitors in cholangiocarcinoma cell lines.
Oncol Lett
March 2025
Program in Translational Medicine, Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samutprakarn 10540, Thailand.
Cholangiocarcinoma (CCA) is a biliary tract carcinoma that is challenging to treat due to its heterogeneity and limited treatment options. Genetic alterations in DNA damage response (DDR) pathways and homologous recombination (HR) defects are common in CCA. This has prompted interest in the use of ataxia telangiectasia and Rad3-related protein (ATR) and poly(ADP-ribose) polymerase (PARP) inhibitors to treat CCA.
View Article and Find Full Text PDFSeizure network characterization by functional connectivity mapping and manipulation.
Neurophotonics
January 2025
Weill Cornell Medicine, Department of Neurological Surgery, New York, United States.
Significance: Despite the availability of various anti-seizure medications, nearly 1/3 of epilepsy patients experience drug-resistant seizures. These patients are left with invasive surgical options that do not guarantee seizure remission. The development of novel treatment options depends on elucidating the complex biology of seizures and brain networks.
View Article and Find Full Text PDFPD-L1 as a Biomarker in Gastric Cancer Immunotherapy.
J Gastric Cancer
January 2025
Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Combining chemotherapy with immune checkpoint inhibitors (ICIs) that target the programmed death-1 (PD-1) protein has been shown to be a clinically effective first-line treatment for human epidermal growth factor receptor 2 (HER2)-negative and -positive advanced or metastatic gastric cancer (GC). Currently, PD-1 inhibitors combined with chemotherapy are the standard treatment for patients with HER2-negative/positive locally advanced or metastatic GC. Programmed death-ligand 1 (PD-L1) expression, as assessed using immunohistochemistry (IHC), is a crucial biomarker for predicting response to anti-PD-1/PD-L1 agents in various solid tumors, including GC.
View Article and Find Full Text PDFA Phage-Based Approach to Identify Antivirulence Inhibitors of Bacterial Type IV Pili.
Microb Biotechnol
January 2025
Department of Biological Sciences, Virginia Tech, Blacksburg, Virginia, USA.
The increasing threat of antibiotic resistance underscores the urgent need for innovative strategies to combat infectious diseases, including the development of antivirulants. Microbial pathogens rely on their virulence factors to initiate and sustain infections. Antivirulants are small molecules designed to target virulence factors, thereby attenuating the virulence of infectious microbes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!